Form 4: Pulmonx Director Tiffany Sullivan Receives Significant RSU Grant

Pulmonx Corporation Director Tiffany Sullivan was granted 37,153 shares of common stock in the form of Restricted Stock Units, increasing her direct beneficial ownership to 75,199 shares.

Summary

• Tiffany Sullivan, a Director of Pulmonx Corporation (LUNG), acquired 37,153 shares of common stock on June 2, 2025.
• This acquisition was an RSU Grant, meaning the shares were acquired at a price of $0.
• Following this transaction, Ms. Sullivan directly beneficially owns a total of 75,199 shares of Pulmonx common stock.
• The RSU Grant vests on the earlier of June 2, 2026 (the one-year anniversary of the grant date) or the date of the Annual Meeting of Stockholders for the year subsequent to the grant.
• The Form 4 filing was signed by David Aaron Lehman, Attorney-in-Fact for Tiffany Sullivan, on June 3, 2025.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is generally a positive sign, indicating alignment of interests and standard compensation practices, though it's a routine disclosure rather than a performance announcement.

Positives

• The grant of Restricted Stock Units to a director aligns the director's interests with long-term shareholder value.
• Increased direct beneficial ownership by a director can signal confidence in the company's future prospects.

Future Outlook

The RSU grant includes a vesting schedule, indicating that the shares will become fully owned by the director on the earlier of June 2, 2026, or the date of the Annual Meeting of the Stockholders for the year subsequent to the grant, aligning future compensation with company performance.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically an equity grant to a director. Such grants are common practice across industries, including the medical device sector where Pulmonx operates, as a form of executive and director compensation designed to align interests with shareholders.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a standard practice in corporate governance and executive compensation across various industries, including medical technology.
• While specific comparable companies or projects are not detailed in this filing, RSU grants are widely used by companies like Medtronic, Intuitive Surgical, and Stryker to incentivize long-term performance and retain key personnel.
• The vesting schedule (one-year anniversary or next annual meeting) is also a common structure for such grants, reflecting typical industry benchmarks for director equity compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, potentially encouraging long-term value creation and demonstrating commitment to the company's performance.

Next Steps

• The RSU Grant is expected to vest on the earlier of June 2, 2026, or the date of the Annual Meeting of the Stockholders for the year subsequent to the grant.

Key Dates

Keywords

Pulmonx Corporation, LUNG, Form 4, SEC filing, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Stock Ownership, Corporate Governance